Old and New Biomarkers in Idiopathic Recurrent Acute Pericarditis (IRAP): Prognosis and Outcomes.

IF 3.1 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Current Cardiology Reports Pub Date : 2025-01-11 DOI:10.1007/s11886-024-02170-y

Ruggiero Mascolo, Emanuele Bizzi, Martina Martelli, Chiara Facoetti, Giulia Colazzo, Fabio Barone, Antonio Brucato

{"title":"Old and New Biomarkers in Idiopathic Recurrent Acute Pericarditis (IRAP): Prognosis and Outcomes.","authors":"Ruggiero Mascolo, Emanuele Bizzi, Martina Martelli, Chiara Facoetti, Giulia Colazzo, Fabio Barone, Antonio Brucato","doi":"10.1007/s11886-024-02170-y","DOIUrl":null,"url":null,"abstract":"Purpose of review: To outline the latest discoveries regarding the utility and reliability of serum biomarkers in idiopathic recurrent acute pericarditis (IRAP), considering recent findings on its pathogenesis. The study highlights the predictive role of these biomarkers in potential short- (cardiac tamponade, recurrences) and long-term complications (constrictive pericarditis, death).Recent findings: The pathogenesis of pericarditis has been better defined in recent years, focusing on the autoinflammatory pathway. New studies have demonstrated the pivotal role of the classical inflammatory biomarkers in distinguishing pericarditis phenotypes (high-grade vs. low-grade inflammation) and in defining outcomes of this condition. Pericarditis involves intense inflammatory activity, which causes elevation of different markers, such as C-reactive protein, erythrocyte sedimentation rate, neutrophils and platelets, serum amyloid A and D-Dimer. Conversely, lymphocytes are often reduced, as well as hemoglobin during the acute phase. Cardiac troponins T and I are elevated in up to 30% of cases. A Biomarker for CRP-negative cases is needed. Other markers have been proposed for diagnosis and prognosis in IRAP, such as anti-heart antibodies and anti-intercalated disk antibodies, but we need further studies to validate them.","PeriodicalId":10829,"journal":{"name":"Current Cardiology Reports","volume":"27 1","pages":"17"},"PeriodicalIF":3.1000,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11724782/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Cardiology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11886-024-02170-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: To outline the latest discoveries regarding the utility and reliability of serum biomarkers in idiopathic recurrent acute pericarditis (IRAP), considering recent findings on its pathogenesis. The study highlights the predictive role of these biomarkers in potential short- (cardiac tamponade, recurrences) and long-term complications (constrictive pericarditis, death).

Recent findings: The pathogenesis of pericarditis has been better defined in recent years, focusing on the autoinflammatory pathway. New studies have demonstrated the pivotal role of the classical inflammatory biomarkers in distinguishing pericarditis phenotypes (high-grade vs. low-grade inflammation) and in defining outcomes of this condition. Pericarditis involves intense inflammatory activity, which causes elevation of different markers, such as C-reactive protein, erythrocyte sedimentation rate, neutrophils and platelets, serum amyloid A and D-Dimer. Conversely, lymphocytes are often reduced, as well as hemoglobin during the acute phase. Cardiac troponins T and I are elevated in up to 30% of cases. A Biomarker for CRP-negative cases is needed. Other markers have been proposed for diagnosis and prognosis in IRAP, such as anti-heart antibodies and anti-intercalated disk antibodies, but we need further studies to validate them.

查看原文本刊更多论文

特发性复发性急性心包炎（IRAP）的新旧生物标志物：预后和结局。

综述的目的：考虑到最近在特发性复发性急性心包炎（IRAP）发病机制方面的发现，概述了关于血清生物标志物在IRAP中的实用性和可靠性的最新发现。该研究强调了这些生物标志物在潜在的短期（心脏填塞、复发）和长期并发症（缩窄性心包炎、死亡）中的预测作用。近年来心包炎的发病机制得到了更好的定义，主要集中在自身炎症途径上。新的研究已经证明了经典炎症生物标志物在区分心包炎表型（高级别与低级别炎症）和确定心包炎结局方面的关键作用。心包炎涉及强烈的炎症活动，引起不同标志物的升高，如c反应蛋白、红细胞沉降率、中性粒细胞和血小板、血清淀粉样蛋白A和d -二聚体。相反，淋巴细胞和血红蛋白在急性期经常减少。心脏肌钙蛋白T和I在高达30%的病例中升高。需要一种crp阴性病例的生物标志物。其他的诊断和预后指标，如抗心脏抗体和抗嵌入盘抗体，已被提出，但我们需要进一步的研究来验证它们。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Cardiology Reports CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

6.20

自引率

2.70%

发文量

209

期刊介绍： The aim of this journal is to provide timely perspectives from experts on current advances in cardiovascular medicine. We also seek to provide reviews that highlight the most important recently published papers selected from the wealth of available cardiovascular literature. We accomplish this aim by appointing key authorities in major subject areas across the discipline. Section editors select topics to be reviewed by leading experts who emphasize recent developments and highlight important papers published over the past year. An Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research. We also provide commentaries from well-known figures in the field.